

#8 Pre



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 014643-010510US

Assistant Commissioner for Patents  
Washington, D.C. 20231

On November 7, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]

RECEIVED  
JAN 15 2002  
TECH CENTER 1600/2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alan J Korman *et al.*

Application No.: 09/644,668

Filed: August 24, 2000

For: HUMAN CTLA-4 ANTIBODIES  
AND THEIR USES

Examiner: Not yet assigned

Art Unit: 1632

COMMUNICATION UNDER

37 C.F.R. § 1.821-1.825

and

PRELIMINARY AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, mailed October 2, 2001, Applicants submit herewith the required computer readable and paper copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

✓  
Please replace the paragraph beginning on page 7, line 7, with the following amended paragraph:

Some human sequence antibodies of the invention comprise heavy chain CDR1, CDR2, and CDR3 sequences, SYTMH (SEQ ID NO:27),

QC 505 51